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Abstract
Introduction: A combination of gene and cell therapies has the potential to significantly enhance the therapeutic
value of mesenchymal stem cells (MSCs). The development of efficient gene delivery methods is essential if MSCs
are to be of benefit using such an approach. Achieving high levels of transgene expression for the required period
of time, without adversely affecting cell viability and differentiation capacity, is crucial. In the present study, we
investigate lentiviral vector-mediated genetic modification of rat bone-marrow derived MSCs and examine any
functional effect of such genetic modification in an in vitro model of ischaemia.
Methods: Transduction efficiency and transgene persistence of second and third generation rHIV-1 based lentiviral
vectors were tested using reporter gene constructs. Use of the rHIV-pWPT-EF1-a-GFP-W vector was optimised in
terms of dose, toxicity, cell species, and storage. The in vivo condition of ischaemia was modelled in vitro by
separation into its associated constituent parts i.e. hypoxia, serum and glucose deprivation, in which the effect of
therapeutic gene over-expression on MSC survival was investigated.
Results: The second generation lentiviral vector rHIV-pWPT-EF1-a-GFP-W, was the most efficient and provided the
most durable transgene expression of the vectors tested. Transduction with this vector did not adversely affect
MSC morphology, viability or differentiation potential, and transgene expression levels were unaffected by
cryopreservation of transduced cells. Over-expression of HSP70 resulted in enhanced MSC survival and increased
resistance to apoptosis in conditions of hypoxia and ischaemia. MSC differentiation capacity was significantly
reduced after oxygen deprivation, but was preserved with HSP70 over-expression.
Conclusions: Collectively, these data validate the use of lentiviral vectors for efficient in vitro gene delivery to MSCs
and suggest that lentiviral vector transduction can facilitate sustained therapeutic gene expression, providing an
efficient tool for ex vivo MSC modification. Furthermore, lentiviral mediated over-expression of therapeutic genes in
MSCs may provide protection in an ischaemic environment and enable MSCs to function in a regenerative manner,
in part through maintaining the ability to differentiate. This finding may have considerable significance in
improving the efficacy of MSC-based therapies.
Introduction
Mesenchymal stem cells (MSCs) represent a significant
area of interest in the field of cell therapy. They are a
multipotent, self-renewing cell population isolated from
bone marrow, capable of differentiation into cells of dif-
ferent lineages including chondrocytes, osteoblasts and
adipocytes [1]. The involvement of MSCs in tissue
repair, their ability to home to sites of injury after sys-
temic delivery [2,3] and their evasion of normal host
immune responses [4,5] make them an attractive cell
type for transplantation into various disease models.
MSCs have also generated considerable attention in
recent years in the gene therapy area, as possible vehi-
cles for the delivery of therapeutic genes to sites of
injury. Genetic modification of MSCs may allow further
improvement of their therapeutic potential through pro-
motion or suppression of gene expression. An additional
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of immunogenicity, which would confer significant
advantage to gene therapy techniques, as the MSC itself
may prevent a vector-induced host immune response
[5-7].
Current cell-based therapeutic approaches for cardio-
vascular injury and disease are promising, although not
without their shortcomings. MSC transplantation to the
infarcted heart aims to promote repair and regeneration
of the damaged cardiac tissue. Although several studies
have proved somewhat successful [8], it may be possible
to equip the MSCs for the in vivo environment into
which they will be transplanted. Conditions of hypoxia,
ischaemia and oxidative stress are associated with the
infarct and its surrounding environment. In vitro studies
have shown that, in the absence of oxygen, MSCs are
capable of survival for a limited time [9]. A more pro-
longed lifespan may be necessary for MSCs to exert a
desired therapeutic effect in vivo.I nt h i sr e s p e c t ,w e
hypothesize that increasing MSC survival capacity by
genetic modification could afford the MSC a longer
time in which to mediate repair and recovery both by
direct and paracrine means, thereby enhancing their
in vivo therapeutic value.
MSCs have been modified by various methods
including lipid transfection and viral transduction. It is
necessary to tailor the vector type chosen for MSC
modification to the specific applications for which the
cells are to be used. Lipid transfection of MSCs results
in relatively low numbers of transgene expressing cells,
approximately 30-40% maximum [10]. Modification
with viral vectors generally results in higher efficiency
that may express transgene long or short term,
depending on choice of vector. Our group has pre-
viously published a study comparing various in vitro
modification methods for rat MSCs. It was reported
that lentiviral vectors demonstrated excellent transduc-
tion of rat MSCs in contrast to adenovirus, AAV, lipid
transfection and electroporation [11]. Accurate knowl-
edge of gene transfer performances, in particular vec-
tor and promoter efficiency, is central to paving the
way to preclinical and eventually human trials.
Lentiviral vectors have long since been established as
h a v i n gt h ea b i l i t yt ot r a n s d u c eab r o a dr a n g eo fc e l l
types efficiently, including non-dividing, senescent and
terminally differentiated cells [12,13]. Lentiviral vectors
integrate into the host cell genome resulting in stable
long-term transgene expression. Elements to be consid-
ered upon choosing a vector type include vector genera-
tion, vector envelope and promoter type. An additional
important consideration with regard to viral vector gene
delivery is the possibility of epigenetic transgene sup-
pression or inactivation by target host cells after trans-
duction has occurred. This is of particular concern, as
its occurrence may adversely affect the use of viral vec-
tors for ex vivo stem cell modification.
The present study aims to assess lentivirus vector-
mediated genetic modification of MSCs, specifically
transduction efficiency, durability of transgene expres-
sion and transgene or promoter “silencing” of three dif-
ferent lentiviral vector constructs. In addition, the effect
of lentiviral vector transduction on MSC viability and
differentiation capacity was examined. The effects of cell
cryopreservation, cell passage number and species on
transgene expression were also assessed. Further to
establishing an optimal vector system for the modifica-
tion of MSCs, a second objective of this study was to
gain an understanding of how MSCs react to and influ-
ence post-ischaemic recovery, and to ascertain if this
can be enhanced by induced therapeutic antioxidant or
anti-apoptotic gene over-expression. This series of
experiments included an evaluation of the survival and
differentiation potential of MSCs in an in vitro model of
ischaemia and its components, the main goal being to
determine whether lentivirus vector-mediated over-
expression of the pro-survival proteins catalase, SOD1,
SOD3 and HSP70 can facilitate increased MSC survival.
Materials and methods
All reagents utilised were from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise stated.
Lentivirus production & titration
The present study compared second and third genera-
tion self-inactivating (SIN) human immunodeficiency
virus-1-based (HIV-1), VSV-G pseudotyped lentiviral
vectors. Tat-dependent second generation lentiviral vec-
tors consisted of rHIV-pWPT-EF1-a-GFP-W and rHIV-
cPPT-CMV-GFP-W. The associated second generation
packaging system production plasmids were provided by
Didier Trono (Lausanne, Switzerland). Vectors were
produced by standard transient transfection of a three-
plasmid system into producer cells. Briefly, packaging
plasmid ps-PAX2.2 (Addgene plasmid 12260), envelope
plasmid pMD2.G (Addgene plasmid 12259) and either
pWPT-GFP (Addgene plasmid 12255) or cPPT-CMV-
GFP expression plasmids were transfected into HEK293
cells using Jet PEI transfection reagent (Polyplus Trans-
fection Inc, NY, USA) according to manufacturer’s
instructions. Culture medium was replaced 16 h post-
transfection. Vector-containing supernatants were col-
lected 48 h and 72 h post-transfection, filtered, pooled
a n dc o n c e n t r a t e db yu l t r a c e ntrifugation at 27,000 × g
for 3 h. Lentivirus vector titre was determined by a
quantitative real-time PCR based method, which
detected stably integrated virus sequences in target
HeLa cells and was expressed as transducing units per
ml (TU/ml). Tat-independent third generation lentivirus
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element and polypurine tract with the GFP transgene
under the control of the PGK promoter was produced
by Genethon (Genethon, Évry Cédex, France, ref.
pG3.22116) using four-plasmid transfection of 293T
cells. Human Catalase, HSP70, SOD1 and SOD3 genes
were cloned into the lentiviral expression plasmid
pWPT using MluI and SalI restriction sites and lenti-
viral vectors expressing these transgenes were produced
and vector titre calculated as described above.
Human mesenchymal stem cell isolation and expansion
Marrow was obtained from donors after informed con-
sent and all procedures were approved by the Clinical
Research Ethics Committee at University College Hospi-
tal (Galway, Ireland). Briefly, 30 ml heparin-treated bone
marrow aspirates were acquired in separate 6 ml ali-
quots from the iliac crest of healthy donors. Aliquots
were pooled, washed in PBS and cell pellets were resus-
pended in 10 ml of complete human MSC medium,
which consisted of low glucose DMEM, 10% (v/v) FBS
and 1% penicillin/streptomycin mix. Cells were seeded
into 175 cm
2 flasks at a density of 5.7 × 10
5 cells per
cm
2. After 5 days, non-adherent red blood cells were
removed by a PBS wash and cells were re-fed with
30 ml of complete medium per flask. When MSC colo-
nies had reached 80-90% confluence, cells were detached
with 0.25% trypsin(w/v)/1 mM EDTA solution, re-plated
at 5.7 × 10
3 cells per cm
2 with subsequent subculture,
usually at 4-6 day intervals.
Rat mesenchymal stem cell isolation and expansion
All procedures involving animals were performed in
accordance with the ethical regulations of the National
University of Ireland (Galway, Ireland). MSCs were iso-
lated from the bone marrow of 8-12 weeks old male
Sprague Dawley rats (Harlan Laboratories, Oxfordshire,
UK) as previously described [14-16]. Briefly, after
euthanasia, marrow was flushed from femoral and
tibial compartments with complete rMSC growth med-
ium, which consisted of 44.5% a-MEM (Gibco, Invitro-
gen, Carlsbad, CA, USA) and 44.5% F12-Ham (Gibco),
supplemented with 10% FBS (Gibco) and 100 U/ml
penicillin-G and 100 μg/ml streptomycin sulphate
(Gibco). Recovered suspensions were pooled, counted
a n dp l a t e da tad e n s i t yo f1 . 2×1 0
6 cells per cm
2.
Non-adherent cells were removed after 3 days and
cells were re-fed with complete rMSC medium, with
additional media changes every 3-4 days. After
approximately 8 days or when cell cultures reached
confluence, cells were detached with 0.25% trypsin(w/
v)/1 mM EDTA solution and re-plated at 5.7 × 10
3
cells per cm
2, with subsequent passage when they
again reached confluence.
MSC characterisation
The ability to differentiate down the adipogenic, osteo-
genic and chondrogenic lineages, following isolation
procedures described, was routinely tested in-house.
According to criteria recommended by the International
Society for Cellular Therapy (ISCT), an MSC deemed
acceptable for laboratory based investigations and pre-
clinical studies is defined by its adherence to plastic, dif-
ferentiation capacity and cell surface markers (CD105,
CD73, CD90 positive and CD34, CD45, CD14 or
CD11b, CD79a or CD19 and HLA-DR negative). Iso-
lated MSCs were routinely characterised in-house by
flow cytometry for their cell surface markers, as pre-
viously described [10,11].
MSC transduction and gfp reporter gene detection
MSCs were seeded in 6-well plates at 1 × 10
5 cells per
well, grown overnight and transduced with lentiviral
vectors in a minimal volume of medium. MSCs were
harvested for analysis, at the earliest, 96 h post-trans-
duction. For the 28-day transgene analysis experiments,
cells were harvested at 7 d intervals, at which point each
cell population per well was split, using one half to
maintain the cells in culture and the other for GFP
expression analysis (see below). For assessment of trans-
gene silencing, transduced cell populations were cul-
tured in medium containing the histone deacetylase
(HDAC) inhibitor, trichostatin A (TSA; 100 nM) and/or
the DNA methyltransferase inhibitor 5-azacytidine (5-
aza-c; 5 μM) for the 28-day period, harvesting at 7 d
intervals. MSCs were harvested by trypsinisation, fixed
in 4% paraformaldehyde and resuspended in PBS. Per-
centage GFP-positive cells and their mean fluorescence
intensity (MFI) was determined using Guava Express
Plus analysis on a GuavaEasyCyte™ flow cytometer
(Guava Technologies, Millipore, Billerica, MA, USA).
Total GFP was calculated by multiplication of the per-
centage GFP positive cells by the MFI.
Therapeutic transgene expression analysis
Rat MSCs were transduced by incubation with lentiviral
vectors at a multiplicity of infection (MOI) of 100 for
18 hours. Transgene expression was measured 72 h
post-transduction by immunofluorescent staining and
Western blot analysis (Figure S1 in Additional file 1).
In vitro ischaemia treatments
To mimic the in vivo scenario of ischaemia, MSC were
exposed to conditions of hypoxia (O2 at 0.5% plus com-
plete DMEM), ischaemia (O2 at 0.5% in serum and glu-
cose free DMEM) and complete O2 and glucose
deprivation by inhibition of glycolysis (ischaemia+2-
deoxyglucose) in an in vivo 400 hypoxia chamber (Rus-
kinn Technologies, UK). 2-deoxyglucose (2DG) is a
McGinley et al. Stem Cell Research & Therapy 2011, 2:12
http://stemcellres.com/content/2/2/12
Page 3 of 18glycolytic inhibitor, which prevents hexokinase phos-
phorylation of glucose. Addition of this inhibitor pro-
vided an in vitro model of complete glucose deprivation.
For these experiments, MSCs were seeded and trans-
duced under normal culture conditions until 72 h
post transduction when cells were optimally expressing
transgene. The appropriate media for each condition
(hypoxia, ischaemia, ischaemia + 2DG) was placed in
the hypoxia chamber for a minimum of 3 hours to
deplete the oxygen levels to the required 0.5%. Depleted
media was added to MSCs, which were treated with the
appropriate conditions for the required period of time.
Assessment of viability and apoptosis
MSC viability was determined by standard MTT assay
as described previously [17]. Apoptosis levels were
assessed by identification of apoptotic nuclei by DAPI
staining of MSCs. Percentage apoptotic cells was deter-
mined in a semi-quantitative manner by counting num-
bers of apoptotic nuclei per field of ten random images.
Caspase-3 activation was also examined using Ac-
DEVD-AFC substrate (Biomol, Enzo Life Sciences, PA,
USA). Staurosporine (STS - at 500 nM for 12 h) was
used as a positive control for caspase activation.
Adipogenesis differentiation assay
MSCs (both transduced and non-transduced) were
seeded at 2 × 10
5 cell per well in 6-well plates. Once
cells had reached confluence, adipogenic differentiation
was induced by three 72 h cycles of adipogenic induc-
tion media (1 μM dexamethasone, 10 μg/ml insulin, 200
μM indomethacin, 500 μM 3-isobutyl-1-methyl-
Xanthine, 100 U/ml penicillin, 100 μg/ml streptomycin,
10% FBS and 5% rabbit serum in high-glucose DMEM).
Following each round of induction, cells were main-
tained in maintenance medium for 24 h (10 μg/ml insu-
lin in complete high glucose medium), and for 5-7 days
after final induction. Cells were fixed in 10% formalin
and differentiated cells were identified by Oil Red O
stain for lipid vacuoles. Images of 10 random fields for
each well were acquired and differentiated cells contain-
ing stained lipid vacuoles per microscope field were
counted. Oil Red O stain was also quantified by extrac-
tion of the stain into 99% isopropanol and absorbance
measurement on a Wallac plate reader at 490 nm. Non-
induced MSCs, maintained in normal growth medium,
were included as negative controls for the adipogenesis
assay.
Statistical analysis
Data are presented as mean ± standard deviation (n =3 )
of three independent experiments. Statistical analyses
were carried out on data sets using SigmaStat for Win-
dows, version 3.5. One-way analysis of variance
(ANOVA) was used to determine statistical significance
between groups, followed by multiple paired compari-
sons for normally distributed data (Tukey Test). Non-
normally distributed data were analysed by ANOVA on
ranks using either Dunn’s Test or Kruskal-Wallis. Paired
t-tests were used for pairwise comparisons. Values of
p < 0.05 were considered statistically significant (*p <
0.05, **p < 0.001).
Results
Lentiviral vector efficiency in rat MSCs
Of the vectors evaluated, it was determined that the sec-
ond generation VSV-G pWPT-EF1-a-GFP-W was the
most efficient at rat MSC transduction. At MOI 100,
this vector gave transduction efficiencies of 90-98% at 7,
14, 21 and 28 days respectively (Figure 1A), and total
GFP values of over 75,000 at all time points (Figure 1B).
This vector consistently mediated high level, sustained
GFP transgene expression levels with no significant
reduction throughout the time frame analysed. This was
in contrast to the rHIV-cPPT-CMV-GFP-W and rHIV-
PPT-PGK-GFP-W lentiviral vectors, which were tested
in parallel, and consistently gave percentage GFP posi-
tives of 1-5% and 35-40% (Figure 1A), and total GFP
values of 4,552-186 and 28,866-15,806 (Figure 1B)
respectively. These significantly lower values were
observed at all MOIs tested (data not shown).
Lentiviral vector transgene silencing in rat MSCs
Silencing of vector transgene is an important factor to
consider where long term stable expression of transgene
is required in target cells. Here, the reactivation potential
of reporter transgene was assessed over a 28-day time
period, by treatment of transduced cells with the HDAC
inhibitor TSA, and the DNA methyltransferase inhibitor
5-aza-c. The existence of vector silencing was indicated
by an increase in reporter gene expression detectable by
FACS, following release of promoter function after drug
treatment (Figure 2). TSA and 5-aza-c treatment of
rHIV-cPPT-CMV-GFP-W transduced rMSCs resulted in
significant increases of GFP positive cells at an MOI of
100, indicating that reporter transgene may have been
reactivated upon exposure to the methylation and deace-
tylation inhibitors (Figure 2A). TSA exposure increased
the percentage of GFP positive cells at all time points,
these increases were significant at day 14 and day 28 (p <
0.05). At all measured time points, treatment with 5-aza-
c significantly increased GFP transgene expressing cell
numbers compared to non-treated control cells, with the
largest observed increases at day 14 and day 21 (p <
0.001). Although there were increases in rHIV-PPT-
PGK-GFP-W vector transduction levels (Figure 2B),
these were not significant compared to controls. Like-
wise, there were no apparent changes in transgene
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Figure 1 Lentivirus vector efficiency in rat MSC. (A) Percentage GFP positive cells and (B) total GFP (mean fluorescent intensity X % GFP
positive cells) in MSCs after transduction with the described lentivirus vectors over a 28 day period with no selection methods at MOI 100. Data
are shown as mean ±SD (n = 3) of three independent experiments. *p < 0.05, **p < 0.001 rHIV-pWPT-Ef1-a-GFP-W vector vs. PGK and CMV
promoter-containing vectors.
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duced MSCs (Figure 2C), which suggests that transgene
silencing is not a significant issue with respect to these
particular constructs. Similar results were observed at
other MOIs tested (data not shown).
Transduction with second generation pWPT-EF1-a-GFP-W
lentiviral vector does not affect viability or differentiation
potential
Toxicity of the vectors, following transduction was ana-
lysed by measurement of cell viability, using MTT assay
(Figure 3A). No significant adverse effect on cell viability
was apparent when compared to non-transduced control
cells. Increase of viral dose resulted in an expected
increase in cell death, but these numbers always
remained low, with a percentage cell death of only ~5%
being seen at the maximal MOI of 100.
MSC differentiation capacity was determined by lipid
vacuole formation after a 21-day adipogenesis assay (Fig-
ure 3B,C,D). Under normal culture conditions, MSCs
transduced with the rHIV-pWPT vector underwent adi-
pogenesis at the same efficiency as control non-trans-
duced MSCs (Figure 3B,C,D). Inhibitory effects on rat
MSC adipogenic differentiation ability were not
observed, either in terms of numbers of differentiated
cells (Figure 3C) or amount of lipid vacuoles measured
spectrophotometrically (Figure 3D).
Factors affecting transgene expression in pWPT-EF1-a-
GFP-W modified MSCs
A significant dose response, with increasing virus parti-
cle concentration from MOI 1 to MOI 100 (p < 0.05),
was achieved in rat MSCs transduced with rHIV-
pWPT-EF1-a-GFP-W vector, as expected. The percen-
tage of GFP-positive MSCs increased from ~17% at
MOI 1 to ~98% at MOI 100 (Figure 4A). The effect of
MSC passage number on pWPT-Ef1-a-GFP-W trans-
duction efficiency and transgene expression was ana-
lysed by transduction of rat MSCs of early and late
passage numbers and determination of numbers of
transduced cells by FACS analysis. Here, a difference in
transgene expression levels between the passage num-
bers was apparent (Figure 4B). At both MOIs measured,
there were significant differences between early and late
MSC passage numbers. At MOI 50, there was a
decrease of approximately 15% in P5 and 13% in P4
MSCs compared to P1 MSC populations (p < 0.05). At
the higher MOI of 100, a similar decrease in percentage
transduced cells with increasing passage number was
observed, however this was only significant between P1
and P5 MSC populations, with a reduction of approxi-
mately 8% (p < 0.05). A direct comparison was made
between rat and human MSCs, which had been trans-
d u c e da tM O I5 0a n dM O I1 0 0b yp W P T - E F 1 - a-GFP-
W lentiviral vector (Figure 4C). There was no significant
difference found between transduction levels in human
and rat MSCs, at either MOI tested. The effect of cryo-
preservation on transduced rMSC populations was also
examined (Figure 4D), where no negative impact on
transgene GFP expression was detected.
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Figure 2 TSA/5-AZA-C treatment on GFP transgene expression
in lentiviral vector modified rat MSCs over 28d. (A) rHIV-cPPT-
CMV-GFP-W transduced rMSC at MOI 100. (B) rHIV-pWPT-EF1-a-GFP-
W transduced rMSC at MOI 100. (C) rHIV-PPT-PGK-GFP-W transduced
rMSC at MOI 100. Data are shown as mean ±SD (n = 3) of three
independent experiments. *p < 0.05, **p < 0.001 vs. no drug.
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MSC viability was detected by MTT assay after exposure
to hypoxic conditions (Figure 5A). MSC viability
decreased with increasing hypoxia exposure time, from
approximately 97% at 12 hours of hypoxia to ~60% at
96 h. Transduction with the HSP70 lentiviral vector,
and consequent HSP70 over-expression, significantly
increased percentage viability at both 72 h and 96 h of
hypoxia compared to non-transduced and GFP control
MSCs (p < 0.05). Catalase and SOD over-expression did
not increase viability to the same extent as HSP70,
although at 48 h SOD1-MSCs were more viable than
controls (p < 0.05). Control GFP MSC percentage viabi-
lity remained similar to that of non-transduced MSCs,
proving that any observed effects were as a result of
transgene over-expression and not due to the lentiviral
vector itself.
The effect of HSP70 over-expression on hypoxia-
induced apoptosis was also assessed. Classical signs of
apoptotic cell death were visible with respect to nuclear
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Figure 4 Factors affecting transgene expression in rHIV-pWPT-EF1-a-GFP-W vector modified MSCs. (A) Significant dose response (*p <
0.05 vs. MOI0) with increasing MOI (1-100) following rHIV-pWPT-EF1-a-GFP-W transduction of rMSC. (B) Effect of rMSC passage number on
lentiviral vector transduction efficiency (*p < 0.05 vs. P1 cells). (C) Comparison of lentiviral vector transduction of human and rat MSCs. (D) Effect
of cryopreservation on GFP transgene expression levels. Data are shown as mean ±SD (n = 3) of three independent experiments.
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activity in MSC after 48 h and 72 h hypoxia (*p < 0.05 HSP70-MSCs vs. non-transduced MSC). Data are shown as mean ±SD (n =3 )o ra s
representative images of three independent experiments.
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shaped” nuclear membranes, intense fluorescence indi-
cative of nuclear condensation, nuclear fragmentation
and disassembly into apoptotic bodies (Figure 5B). The
percentage of apoptotic cells was also calculated from
these images (Figure 5C). A significant increase in apop-
totic nuclei was evident after 72 h of hypoxia, at which
point numbers were significantly reduced in the HSP70
group compared to controls (p < 0.001). The morpholo-
gical changes indicative of apoptosis were confirmed by
caspase activity measurement at 48 and 72 hours of
hypoxia (Figure 5D). At 48 h there was no apparent
increase in caspase activity in either the non-transduced
or transduced MSC groups. At 72 h, there was a signifi-
cant increase in caspase activity across the groups,
which was significantly reduced in transduced MSCs
that were over-expressing HSP70, compared to control
MSCs (p < 0.05).
Ischaemia
Not unexpectedly, MSCs were more sensitive to condi-
tions of ischaemia than hypoxia (Figure 6A). After
12 hours of ischaemia, cell viability had decreased to
approximately 70%, falling to 20% by 96 h. Exogenous
expression of HSP70 produced a significantly higher per-
centage of viable MSCs at several time points compared
to control groups at 96 h (p < 0.05). No significant
increases in viability were measured for catalase or SOD
modified MSCs compared to controls at any time point.
An increase in apoptotic nuclei number was apparent as
ischaemia exposure time increased (Figure 6B). Fewer
a p o p t o t i cn u c l e iw e r ep r e s e n ti nt h eH S P 7 0g r o u pa t
48 h and 72 h (Figure 6C), which was significant com-
pared with controls (p < 0.001). Increased caspase-3
activity was observed across all MSC groups exposed to
ischaemia at the 48 h and 72 h time points examined
(Figure 6D). Caspase activity was significantly decreased
in HSP70-MSCs compared to non-transduced and
GFP-MSC controls (p < 0.05).
Ischaemia and 2-deoxyglucose (2DG)
To mimic the in vivo scenario of ischaemia where cells
may not be able to use glycolysis for ATP level mainte-
nance, MSCs were treated with 1 mM 2DG in addition
to the conditions of ischaemia previously described.
Addition of 2DG exacerbated the observed effects on
MSC survival in terms of viability and apoptosis. After
12 hours of treatment, viability of unmodified MSCs
had decreased below 40%, falling to less than 10% at the
latest time point examined (Figure 7A).
At the early time points of 12 and 24 hours, the
HSP70-MSC group displayed significantly increased via-
bility, compared to controls at 24 h (p < 0.001). There
was no apparent effect of exogenous HSP70 expression
at any later time points. Analysis of nuclear morphology
showed that increased numbers of apoptotic cells were
present with ischaemia + 2DG exposure compared to
the previous treatments (Figure 7B). Numbers of apop-
totic nuclei were significantly reduced in the HSP70
group compared to controls at 48 h (p < 0.05) and 72 h
(p < 0.001) (Figure 7C). Caspase 3 activity levels were
stimulated by ischaemia 2DG treatment and peaked at
48 h, after which activity levels dropped by almost half
( F i g u r e7 D ) .A tb o t ht i m ep o i n t se x a m i n e d ,i n d u c e d
HSP70 over-expression did not offer significant protec-
tion against caspase-3-dependent apoptosis.
Hypoxia, ischaemia and MSC differentiation
The effect of ischaemic stress on MSC differentiation
capacity was determined by lipid vacuole formation after
a 21-day adipogenesis assay. Differentiated cells were
identified by Oil Red O staining for lipid vacuoles
(Figure 8A). MSCs that were exposed to in vitro models
of ischaemia produced fewer lipid vesicles compared to
normoxic MSCs. However, HSP70 over-expression
reduced this inhibitory effect of oxygen, serum and glu-
cose deprivation on MSC adipogenesis. This was in
terms of numbers of differentiated cells (Figure 8B) and
the amount of lipid vacuoles measured (Figure 8C),
compared with controls (p < 0.05, p < 0.001).
Discussion
Genetic modification of MSCs
Numerous studies have utilised genetically engineered
MSCs, which have been modified by various gene ther-
apy vectors including adenovirus [18,19], AAV [20],
non-viral vectors [21,22], and lentivirus [23,24]. Initial
vector transduction efficiency and optimisation studies
are the foundation of future in vivo experiments and
therefore the efficiency of vector transduction of MSCs
determines whether a particular preclinical model is
worth pursuing. In the present study, we compare three
different lentiviral vector types; two second generation
vectors containing either the EF1-a or CMV promoter
and a third generation vector with GFP transgene
expression under control of the PGK promoter. In the
second generation lentiviral vector system, five of the
nine HIV-1 genes are eliminated, retaining genes for vir-
ion structural proteins and enzymes (gag/pol) and genes
relating to transcriptional and post-transcriptional func-
tions (tat and rev). These vectors are produced with a 3
plasmid packaging system. The latest third generation
vectors have further HIV-1 genes deleted leaving only
gag, pol and rev and are produced using a four-plasmid
set. This vector generation has been designed using a
chimeric LTR (long terminal repeat) ensuring transcrip-
tion in the absence of tat. As a result, this vector system
possesses a higher safety profile and is more suitable for
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Figure 6 Enhanced MSC survival by lentiviral vector modification in ischaemia. (A) Percentage rMSC viability as determined by MTT assay
after ischaemia exposure (*p < 0.05 HSP70-MSCs vs. non-transduced MSC). (B) DAPI staining of MSCs after 72 h ischaemia. (C) Percentage
apoptotic nuclei per microscope field (n = 10) (**p < 0.001 HSP70-MSCs vs. non-transduced MSCs at 48 h and 72 h ischaemia). (D) Caspase-3
activity in rMSC after 48 h and 72 h ischaemia (*p < 0.05 HSP70-MSCs vs. non-transduced MSCs). Data are shown as mean ±SD (n =3 )o ra s
representative images of three independent experiments.
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Figure 8 Enhanced MSC differentiation by lentiviral vector modification in hypoxia and ischaemia. (A) Oil Red O staining for lipid
vacuoles post rMSC adipogenic differentiation. There was no negative effect of lentivirus vector transduction and over-expression of GFP or
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Page 13 of 18clinical applications. Vector generation and promoter
type will undoubtedly affect transduction levels - low or
short-lived transgene expression levels, cytotoxicity or
transgene silencing may prompt the choice of an alter-
native vector type or model. Consequently, a full investi-
gation into the ex vivo transduction potential of MSCs
derived from the same species is essential. This series of
experiments set out to assess and optimise lentiviral
vector transduction efficiency in rat MSCs, and also to
examine any functional effect of genetic modification in
an in vitro model of ischaemia.
Gene silencing can present problems when using gene
delivery as certain vectors and promoters have been
shown to be susceptible to transcriptional silencing in
particular host cell types. It is widely accepted that ret-
roviruses are silenced in stem cells [25-28], however, it
remains controversial as to whether HIV-1-based SIN
lentiviral vectors are also subjected to the same effects
[29-32]. There have been several reports that SIN lenti-
viral vectors can be silenced to some degree in embryo-
nic stem (ES) cells [29] and primary murine
hematopoietic stem cells (HSCs) [32], with varying silen-
cing rates but thus far, there have been no definitive
reports of lentiviral vector transgene silencing in
mesenchymal stem cells. This concept of vector trans-
gene silencing is of considerable importance where
stable long-term gene expression is required. Although
the present study is not a conclusive demonstration that
promoter/transgene silencing or inactivation does not
occur, the experimental results suggest that it is not a
major factor to be considered, with respect to rat MSC
transduction by the second generation VSV-G rHIV-
pWPT-EF1-a-GFP-W lentiviral vector. Upon considera-
tion of the collective data from the vector and silencing
experiments, it is clear that the second generation VSV-
G pseudotyped, EF1-a promoter driven construct,
rHIV-pWPT-EF1-a-GFP-W, is the vector of choice for
the successful and efficient in vitro transduction of
MSCs. Modification with this particular vector facili-
tated sustained, persistent and high-level transgene
expression in target rat MSCs, possibly due to various
factors, the most likely being promoter type. Several
in vitro studies have compared promoters in similar len-
tiviral vector constructs and have determined the Ef1-a
promoter to be superior to other promoters tested and
mediate high transgene expression levels [33]. This find-
ing is of particular relevance to the use of MSCs for
ex vivo transplantation in various preclinical models,
where long term gene expression is required. To this
end, this second generation VSV-G rHIV-pWPT-EF1-a-
GFP-W lentiviral vector was chosen for all further MSC
modification in this study.
In addition to assessment of transduction efficiency,
we subsequently sought to examine the survival and
differentiation potential of MSCs modified with this vec-
tor. As expected, a dose-response effect was achieved by
transducing cells with increasing MOI, with levels
approaching 100% transduction being achieved at MOI
100. In addition, we examined any toxic effect that
transduction with this vecto rm a yh a v eo nc e l lv i a b i l i t y
and found that lentiviral vector modification of rat
MSCs had no significant negative effects. Levels of cell
death did not surpass ~5% of total cell population when
transduced with the rHIV-pWPT-EF1-a-GFP-W vector
at a high MOI of 100. This observed low level of cell
death at the highest MOI measured may be in part due
to a toxic effect of transgene rather than toxicity of the
vector itself. GFP expression has previously been docu-
mented as being toxic in various cell types [34]. This
lack of toxicity is significant and advantageous since not
all vector types give the same results, for example gene
transfer by adenovirus, lipid transfection and electro-
poration has been shown to be somewhat toxic to target
cell populations [11]. It is noteworthy that, despite the
integrative nature of lentivirus, modification with
pWPT-EF1-a-GFP-W vector does not have any deleter-
ious effects on fundamental MSC differentiation func-
tion. There was no significant deterioration in
differentiated cell numbers between non-transduced and
transduced MSC populations, clearly demonstrating that
MSC uptake of the VSV-G pseudotyped lentivirus, vec-
tor DNA integration and resultant transgene expression
at a high MOI does not adversely affect MSC plasticity.
The same pattern has been observed with various other
transgenes (data not shown). Based on these data, it is
likely that other differentiation pathways would be
equally unaffected by lentiviral vector modification per
se. Indeed, several studies have similarly observed that
MSC transduction with lentivirus does not negatively
affect osteogenic, chondrogenic or adipogenic differen-
tiation, and that transgene expression is retained in the
differentiated cells [11,35]. This fact further supports the
clinical use of these genetically modified MSCs as gene
delivery vehicles or as an enhanced therapeutic treat-
ment for diseased and damaged tissue.
This study also investigated the effect of MSC trans-
duction at subsequent passages and demonstrated that
MSC passage number is important and affects vector
transduction efficiency in terms of transgene expression
levels. MSC transduction was more efficient at early pas-
sage numbers and was significantly decreased at later
passage numbers. This is of importance for future
experiments, as transduction at earlier passage numbers
ultimately results in higher levels of transgene expres-
sion. It was also determined that cryopreservation of
transduced MSCs had no negative effect on transgene
expression levels. This is of particular relevance to pre-
clinical and human trials, from a logistical perspective,
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expand and freeze, ready for therapeutic use. Other
gene therapy vectors are unsuitable in this respect for
MSC gene delivery, as with certain vectors e.g. adeno-
virus, continued and sustained transgene expression is
not achievable [36]. As preclinical models are designed
with the eventual scale-up to human trials in mind, it is
necessary to examine the transduction of animal cells
compared to cells of human origin. Here, no significant
difference in transgene GFP levels were observed
between human and rat cells, making it possible that
preclinical studies arising from rat MSCs modified with
this lentiviral vector could be translated into future
human studies. These findings on rHIV-pWPT-Ef1-a-
GFP-W MSC transduction are important for the possi-
ble future use of modified MSC in a clinical setting.
In vitro ischaemia (oxygen, serum and glucose
deprivation)
In our investigation of lentivirus transduction of MSCs,
we also sought to demonstrate a functional effect
mediated by lentivirus vector-mediated genetic modifica-
tion. For this, we primarily focused on an in vitro model
of ischaemia, a condition of particular relevance to MSC
transplantation, and several putative pro-survival genes.
In our laboratory, Mylotte et al. demonstrated that
MSCs tolerated in vitro conditions of hypoxia and
ischaemia better than cardiomyocytes and were more
vulnerable to ischaemia induced death rather than that
of hypoxia [9]. This suggests that MSCs may possess the
ability to survive short periods of hypoxia but not
hypoxia with additional glucose and serum deprivation
i.e. ischaemia. This survival capacity may however be
amenable to improvement, by various gene therapy
methods, thereby enhancing MSC therapeutic benefit.
In the present study, we assessed any benefit of
induced therapeutic gene expression to MSCs, in an
in vitro representation of the post-MI state, consisting
of hypoxia and nutrient deprivation. Here, we found
that MSCs tolerated hypoxia relatively well up to 72 h,
after which survival was adversely affected in terms of
cell morphology, viability, cell numbers and apoptosis.
At all time points measured, exposure to ischaemia sig-
nificantly reduced MSC numbers and viability and sig-
nificantly increased apoptosis. Addition of the glycolytic
inhibitor, 2DG, has previously been used to mimic the
inhibition of glycolysis that may occur during in vivo
episodes of ischaemia [37,38]. Thus, 2DG was incorpo-
rated into the aforementioned ischaemia conditions
representing a more severe model of ischaemia. Not
unexpectedly, this most rigorous of all the injury mod-
els, significantly exacerbated MSC death levels compared
to hypoxia and ischaemia, suggesting that glycolysis may
support MSC survival in ischaemia.
All treatments triggered cell death by apoptosis in a
time dependent manner, as identified by morphology
(membrane blebbing, cell and nuclear shrinkage, chro-
matin condensation) and caspase-3 activity. Hypoxia
activated apoptotic cell death at 72 h whereas, under
ischaemic conditions, apoptosis occurred earlier at 48 h
as well as at 72 h. Caspase activation detected in oxygen
and serum-deprived MSCs correlated with time points
where the highest cell death levels were observed, sug-
gesting that MSC death is caspase dependent. These
results were consistent with findings from other
researchers that have observed MSCs to be relatively
resistant to hypoxia to a certain point, but sensitive to
ischaemia ± 2DG [9,39]. The models of ischaemia used
in this study are well established [39-42] and combine
the in vivo ischaemia components; hypoxia, serum
deprivation and glucose deprivation. As higher levels of
MSC death occurred in the models that incorporated
serum and glucose deprivation as well as hypoxia, it is
reasonable to conclude that MSCs are more vulnerable
to apoptosis as a result of nutrient and survival growth
factor withdrawal rather than hypoxia alone. With this
in mind, rendering the MSC more resistant to apoptosis
by any means would prove beneficial for the use of
transplanted MSCs in the treatment of MI.
Induced pro-survival Gene Over-Expression
Following preliminary analysis of treatment effect, MSCs
were transduced to over-express high levels of the pro-
survival genes catalase, HSP27, HSP70, SOD1 and
SOD3. The ability of the modified MSCs to tolerate the
treatment conditions of conditions of hypoxia, ischaemia
and ischaemia + 2DG, compared with wild-type MSC
was subsequently examined. Transduced MSC groups
were observed to be more resistant to all treatments
compared to control GFP and unmodified MSC groups
in terms of survival. Cell survival was assessed initially
by MTT viability assay so that the most effective gene
could be focused on for further study. Of the genes
tested, HSP70 over-expression significantly increased
MSC viability in conditions of hypoxia, ischaemia and
ischaemia + 2DG. In order to ascertain the manner of
cell death occurring as a result of hypoxia and ischae-
mia, analysis of nuclear morphology and caspase induc-
tion was performed. The occurrence of apoptosis in
response to in vitro models of hypoxia and ischaemia
has been previously reported [9,39]. We found that
apoptosis was induced by hypoxia at 72 h and not unex-
pectedly occurred earlier in MSCs exposed to ischaemia
and ischaemia + 2DG. Most importantly, we demon-
strated that the induced over-expression of HSP70 pre-
vented MSC death by apoptosis. In response to hypoxia
and ischaemia, there were significantly fewer apoptotic
nuclei present and significantly decreased caspase-3
McGinley et al. Stem Cell Research & Therapy 2011, 2:12
http://stemcellres.com/content/2/2/12
Page 15 of 18activity levels in the HSP70-MSCs compared to controls.
These combined data demonstrate an increased MSC
survival capacity mediated by lentivirus vector-mediated
HSP70 over-expression, in a clinically relevant model of
ischaemia.
MSC differentiation and oxygen deprivation
The effect of oxygen deprivation-induced stress on MSC
differentiation was also assessed. Only the HSP70 gene
was tested in this experiment as its over-expression had
the most positive effect on MSC survival in previous
experiments. Here, it was observed that none of the
three oxygen deprivation treatment conditions comple-
tely diminished the ability of the MSCs to produce lipid
vacuoles. This is consistent with reports that have
showed MSCs retained the ability to differentiate into
osteoblasts and adipocytes post in vitro hypoxia expo-
sure [43-45]. A study by Lennon et al. demonstrated
optimal MSC function at a reduced oxygen concentra-
tion of 5% [46]; this is not entirely unexpected as these
oxygen levels are similar to that of in vivo bone marrow
[47]. Although differentiation capacity was not entirely
eliminated, we observed it to be notably subdued, in
that numbers and incidence of differentiated MSCs were
significantly reduced, most obviously with exposure to
ischaemia and ischaemia + 2DG. Interestingly, HSP70-
MSCs retained their functional differentiation capacity,
as significantly increased numbers of differentiated cells
were observed in this group. Neither did lentiviral vec-
tor-mediated HSP70 over-expression have any negative
impact on MSC adipogenesis under normal conditions.
The low levels of differentiation observed with ischaemic
MSCs was most likely because cell numbers had
decreased so considerably. Perhaps the significantly
increased differentiation levels associated with the
HSP70-MSC group were due to the fact that HSP70
over-expression had a beneficial effect on cell survival,
thereby preserving cell number.
Conclusions
The combination of mesenchymal stem cell therapy and
gene therapy offers an integrated approach towards tis-
sue and organ repair. The success of such a combined
therapy is dependent on the optimum genetic modifica-
tion of MSCs. Consequently, the present study is of par-
ticular interest and validates the choice and use of
lentiviral vectors for this purpose. Here, we report that
MSCs can be efficiently transduced in vitro to express
either reporter gene or variety of therapeutic genes
using a second generation lentiviral vector. This is, to
our knowledge, the first study that systematically exam-
ines lentiviral vector-mediated gene modification of
MSCs. Information arising from such experiments is
crucial to the successful genetic modification of MSCs,
which has the potential to augment their therapeutic
benefit.
The integrative nature of lentiviral vectors does how-
ever raise concerns of a potential risk of insertional
mutagenesis. In this regard, further investigation and
clarification is required and the development of integra-
tion mapping techniques or targeted gene delivery to
avoid potentially oncogenic sites has become desirable.
The use of a non-integrating lentivirus vector is also an
option - these vectors possess a mutated integrase gene,
which results in transient gene expression. Further
development in this area offers the possibility to develop
a novel gene-transfer vector that does not pose the risk
associated with permanent integration into host cells,
yet possesses the efficiency of lentiviral vectors that is
required for effective genetic modification. Despite these
concerns, the value of lentivirus vectors cannot be com-
pletely discounted, as these vectors are currently unsur-
passed in their efficiency of gene delivery to MSCs.
Additionally, we showed that lentivirus vector modifi-
cation of MSCs can exert a functional effect through
over-expression of HSP70 in an in vitro model of
ischaemia. The use of only in vitro testing does however
restrict what conclusions can be reached from the pre-
sent study, as these findings may not translate to an
in vivo situation. Therefore, further in vivo experiments
based on this study are necessary for the identification
of a potentially therapeutic factor for use in ex vivo
stem cell therapy.
In conclusion, we report that lentivirus vectors are a
valuable gene delivery tool and lentivirus-mediated genetic
modification of MSCs has the potential to significantly
augment the therapeutic benefit of MSC-based therapies.
Additional material
Additional file 1: Transgene expression in lentivirus vector modified
MSCs. Transgene expression was demonstrated by immunostaining of (i)
transduced and (ii) non-transduced samples and also by (iii) western blot
for (A) catalase, (B) HSP70, (C) SOD1 and (D) SOD3. Data are
representative images (scale bars 130 μm), of three independent
experiments. Legend: cat = catalase: 65 kDa, H70 = HSP70: 70 kDa, HBA
= Human b Actin 42 kDa, S1 = SOD1: 16 kDa, S3 = SOD3: 25.8 kDa, N/T
= non-transduced rat MSCs.
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